Therapeutic Efficacy Evaluation of Metronidazole and Some Antifungal Agents with Meglumine Antimoniate on Visceral Leishmaniasis by Real-Time Light-Cycler (LC) PCR in BALB/c Mice

Bahashwan, Saleh

doi:10.4314/tjpr.v10i3.2

Cited by 4 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy of terbinafine on L. major was compared between case and control groups and they reported that case group in which Balb/c mice treated with terbinafine had significantly smaller leishmanial lesions (Bahashwan 2011). This trial supported the findings.…”

Section: Discussionsupporting

confidence: 74%

Topical terbinafine in the treatment of cutaneous leishmaniasis: triple blind randomized clinical trial

et al. 2015

View full text Add to dashboard Cite

Leishmaniasis is a spectrum of disease condition with considerable health impacts, caused by different species of Leishmania. This disease is currently endemic in 98 countries and territories in the world. There are many treatment modalities for cutaneous leishmaniasis. The use of topical terbinafine in the treatment of cutaneous leishmaniasis has recently been considered. Eighty-eight participants more than two years old with proven acute CL by a positive direct smear were randomly allocated to one of the two study arms: first group received meglumine antimoniate (Glucantime) 20 mg/kg/day intramuscular injection (IM) plus a placebo ointment (Mahan Vaseline) for 20 days. The second group received meglumine antimoniate (Glucantime) 20 mg/kg/day IM plus topical terbinafine, for 20 days and were monitored closely by dermatologist during the course of the study. Crude regression analysis showed that there was no significant difference between placebo and intervention group regarding partial or complete treatment (partial treatment: HR crude = 1.1, CI 95 % = 0.7-1.7; complete treatment: HR crude = 1.1, CI 95 % = 0.8-1.7). Although, there was no statistically significant different between the two treatment groups, but clinically it seems that the treatment rate in those who receive glucantime plus terbinafine was more effective than the other group. However this rate depended on the type of lesions. As data indicated ulcerated nodules, papules and plaque in experimental group have been completely improved two times faster than placebo group. Ulcerated nodules, nodules and plaque were partially improved faster in those used tebinafine than placebo ointment.

show abstract

Section: Discussionsupporting

confidence: 74%

Topical terbinafine in the treatment of cutaneous leishmaniasis: triple blind randomized clinical trial

et al. 2015

View full text Add to dashboard Cite

show abstract

“…The primary strength of terbinafine can be attributed to the fact that the drug generally exhibits minimal side effects, with occasional reports of taste loss, hepatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, neutropenia, and pancytopenia [54][55][56][57][58]. In an experimental study conducted by Bahashwan et al (2011) in Saudi Arabia, the efficacy of terbinafine on the Leishmania parasite was investigated. By comparing the effects of terbinafine on L. major between case and control groups, it was observed that the case group, where BALB/c mice were administered terbinafine, demonstrated a significant reduction in the size of the leishmanial lesions [59].…”

Section: A Brief Literature Review and Commentsmentioning

confidence: 99%

“…In an experimental study conducted by Bahashwan et al (2011) in Saudi Arabia, the efficacy of terbinafine on the Leishmania parasite was investigated. By comparing the effects of terbinafine on L. major between case and control groups, it was observed that the case group, where BALB/c mice were administered terbinafine, demonstrated a significant reduction in the size of the leishmanial lesions [59]. Farajzadeh et al (2015) investigated the role of oral terbinafine on humans as an alternative option for the treatment of CL, and they showed good results compared to the standard therapy [60].…”

Section: A Brief Literature Review and Commentsmentioning

confidence: 99%

Impetiginous Cutaneous Leishmaniasis after COVID-19 Infection in a Patient with Poor Cardiac Profile: A Case Report and Literature Review

Alotaibi,

Aldossari,

Alnasser

2023

TropicalMed

View full text Add to dashboard Cite

Cutaneous leishmaniasis incidence has been rising in the past couple of decades. Standard therapy often includes antileishmanial drugs; however, due to their low safety and toxicity threshold, alternative treatments are being investigated. The association between COVID-19 and cutaneous leishmaniasis remains unclear and exploring this connection may offer crucial insights into the pathophysiology of and treatment strategies for infected patients. In this article, we describe a case of a male patient with a history of cardiac and other comorbidities who presented with cutaneous leishmaniasis in the form of impetigo-like skin lesions after being infected with COVID-19. Due to the patient’s poor cardiac profile, sodium stibogluconate was not used and an alternative therapeutic approach was employed. The patient was treated with oral terbinafine, cryotherapy on specific lesions, and a course of cephalexin. Following the course of treatment and subsequent follow-up, the patient exhibited complete resolution and healing of the lesions with scarring, and no active lesions or recurrence were observed. This case highlights the potential for alternative treatment strategies for cutaneous leishmaniasis in patients with comorbidities and emphasizes the importance of further research to better understand the link between COVID-19 and cutaneous leishmaniasis.

show abstract

Synthesis and leishmanicidal evaluation of sulfanyl‐ and sulfonyl‐tethered functionalized benzoate derivatives featuring a nitroimidazole moiety

Rodríguez

Gutiérrez

Domínguez

et al. 2020

Archiv der Pharmazie

View full text Add to dashboard Cite

A series of new nitroimidazole-containing derivatives was synthesized by coupling of 2-[2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethylthio]ethanol with diversely substituted benzoic acids. Upon treatment with m-CPBA, 12 of these sulfanyl compounds were further oxidized to their sulfonyl analogs. All the 26 synthetic compounds were examined for in vitro activity against Leishmania (V.) braziliensis and Leishmania (L.) mexicana, and some of them displayed an efficient antileishmanial activity. Among the compounds tested, the catecholic derivative 2-{[2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl]sulfanyl}ethyl 3,4-dihydroxybenzoate (9a, LC 50 = 13 and 11 µM) and the pyrogallolic derivative 2-{[2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl]sulfanyl}ethyl 3,4,5-trihydroxybenzoate (9b, LC 50 = 4 and 1 µM) were the most active ones against the two Leishmania strains. K E Y W O R D S antiproliferative agents, nitroimidazole, synthesis 1 | INTRODUCTION Leishmaniasis is an infectious disease caused by protozoa of the genus Leishmania. A recent review has shown that over 98 countries and territories are endemic for leishmaniasis transmission, with an overall prevalence of 12 million cases. Over 20 Leishmania species known to be infective to humans are transmitted by the bite of infected female phlebotomine sandflies, thus causing three main types of leishmaniasis: visceral (VL), cutaneous (CL), and mucocutaneous (MCL). It is estimated that approximately 0.2-0.4 million of new VL cases and 0.7-1.2 million of new CL cases occur each year. These diseases are responsible annually for approximately S C H E M E 1 Synthesis of the 2-{[2-(1H-imidazol-1-yl)ethyl]sulfanyl}ethyl benzoate derivatives 7a-l and 9a,b 2 of 10 | RODRÍGUEZ ET AL.

show abstract

Therapeutic Efficacy Evaluation of Metronidazole and Some Antifungal Agents with Meglumine Antimoniate on Visceral Leishmaniasis by Real-Time Light-Cycler (LC) PCR in BALB/c Mice

Cited by 4 publications

References 19 publications

Topical terbinafine in the treatment of cutaneous leishmaniasis: triple blind randomized clinical trial

Topical terbinafine in the treatment of cutaneous leishmaniasis: triple blind randomized clinical trial

Impetiginous Cutaneous Leishmaniasis after COVID-19 Infection in a Patient with Poor Cardiac Profile: A Case Report and Literature Review

Synthesis and leishmanicidal evaluation of sulfanyl‐ and sulfonyl‐tethered functionalized benzoate derivatives featuring a nitroimidazole moiety

Contact Info

Product

Resources

About